Initial highly effective therapy for MS: A strong start.

Abstract

In this issue of Neurology® , Buron et al.1 present an article titled “Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.” The goal of this study was to determine the best way to start therapy in patients with multiple sclerosis (MS). The authors examined starting patients on treatment known to be highly effective for MS known as high-efficacy disease-modifying therapies (heDMTs). They wanted to know if this approach is better than beginning with more moderate treatments (known as medium-efficacy disease-modifying therapies [meDMTs]) and intensifying treatment later if needed.